Cell Source, Inc. (CLCS) financial statements (2023 and earlier)
Company profile
| Business Address |
57 WEST 57TH STREET NEW YORK, NY 10019 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| SIC | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete financial analysis Financial benchmarking |
Balance sheet (Statement of financial position) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2015 | 12/31/2014 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 245 | 28 | 19 | 371 | 7 | 19 | |||
| Cash and cash equivalents | 245 | 28 | 19 | 371 | 7 | 19 | |||
| Prepaid expense | 178 | 57 | 39 | 125 | 72 | 75 | |||
| Deferred costs | 125 | ||||||||
| Other current assets | 30 | 30 | 8 | 36 | 135 | 26 | |||
| Total current assets: | 452 | 115 | 66 | 532 | 338 | 121 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | (3) | (3) | 1 | 2 | |||||
| Deferred costs | 28 | ||||||||
| Other undisclosed noncurrent assets | 3 | ||||||||
| Total noncurrent assets: | (3) | 30 | 2 | ||||||
| Other undisclosed assets | 3 | ||||||||
| TOTAL ASSETS: | 452 | 115 | 66 | 532 | 368 | 123 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities, including: | 2,182 | 1,327 | 953 | 202 | 586 | 234 | |||
| Accounts payable | 193 | 135 | 278 | ||||||
| Accrued liabilities | 1,160 | 1,052 | 533 | 821 | 115 | ||||
| Employee-related liabilities | 10 | 10 | 12 | 12 | 969 | ||||
| Taxes payable | 122 | 118 | 116 | 147 | |||||
| Interest and dividends payable | 697 | 12 | 14 | 109 | 25 | ||||
| Other undisclosed accounts payable and accrued liabilities | (875) | 435 | (735) | ||||||
| Debt | 1,238 | 1,112 | 1,463 | 1,174 | 708 | ||||
| Deferred compensation liability | 724 | 661 | 588 | 627 | 325 | ||||
| Derivative instruments and hedges, liabilities | 352 | 201 | 628 | 3,280 | 2,319 | ||||
| Due to related parties | 150 | 150 | 222 | 150 | 181 | 100 | |||
| Other liabilities | 236 | 100 | 100 | 450 | |||||
| Other undisclosed current liabilities | 4,105 | 1,875 | 2,209 | 520 | 1,254 | ||||
| Total current liabilities: | 8,400 | 5,712 | 3,526 | 5,089 | 6,050 | 3,907 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 72 | ||||||||
| Long-term debt, excluding current maturities | 72 | ||||||||
| Liabilities, other than long-term debt | 4 | ||||||||
| Accounts payable and accrued liabilities | 4 | ||||||||
| Other undisclosed noncurrent liabilities | 145 | ||||||||
| Total noncurrent liabilities: | 145 | 76 | |||||||
| Other undisclosed liabilities | 1,460 | ||||||||
| Total liabilities: | 8,400 | 5,857 | 4,986 | 5,089 | 6,126 | 3,907 | |||
| Stockholders' equity | |||||||||
| Stockholders' equity attributable to parent, including: | (7,947) | (5,742) | (4,920) | (4,557) | (5,758) | (3,784) | |||
| Preferred stock | 1 | 1 | |||||||
| Common stock | 33 | 27 | 26 | 25 | 24 | 24 | |||
| Additional paid in capital | 17,725 | 15,376 | 11,723 | 9,970 | 4,720 | 4,191 | |||
| Accumulated deficit | (25,706) | (21,146) | (16,670) | (14,553) | (10,503) | (7,998) | |||
| Warrants and rights outstanding | 420 | ||||||||
| Other undisclosed stockholders' equity attributable to parent | 1 | 1 | (420) | ||||||
| Total stockholders' equity: | (7,947) | (5,742) | (4,920) | (4,557) | (5,758) | (3,784) | |||
| TOTAL LIABILITIES AND EQUITY: | 452 | 115 | 66 | 532 | 368 | 123 | |||
Income statement (P&L) ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Operating expenses | (3,638) | (3,903) | (2,006) | (2,293) | (2,320) | (4,055) | ||
| Operating loss: | (3,638) | (3,903) | (2,006) | (2,293) | (2,320) | (4,055) | ||
| Nonoperating expense | (922) | (573) | (111) | (790) | (184) | (3) | ||
| Investment income, nonoperating | 17 | (210) | ||||||
| Interest and debt expense | 134 | 194 | (191) | (725) | (36) | |||
| Other undisclosed income (loss) from continuing operations before equity method investments, income taxes | (134) | (194) | (260) | 485 | 36 | |||
| Loss from continuing operations before income taxes: | (4,560) | (4,475) | (2,569) | (3,323) | (2,504) | (4,057) | ||
| Income tax expense (benefit) | 2,424 | 2,524 | 717 | (22) | 646 | 1,151 | ||
| Loss before gain (loss) on sale of properties: | (2,136) | (1,951) | (1,852) | (3,345) | (1,858) | (2,906) | ||
| Other undisclosed net loss | (2,524) | |||||||
| Net loss: | (2,136) | (4,475) | (1,852) | (3,345) | (1,858) | (2,906) | ||
| Other undisclosed net income (loss) attributable to parent | (2,424) | (266) | 263 | (646) | (1,151) | |||
| Net loss attributable to parent: | (4,560) | (4,475) | (2,117) | (3,083) | (2,504) | (4,057) | ||
| Other undisclosed net loss available to common stockholders, basic | (878) | (742) | ||||||
| Net loss available to common stockholders, diluted: | (5,438) | (5,217) | (2,117) | (3,083) | (2,504) | (4,057) | ||
Comprehensive Income ($ in thousands)
| 9/30/2021 TTM | 12/31/2020 | 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2015 | 12/31/2014 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (2,136) | (4,475) | (1,852) | (3,345) | (1,858) | (2,906) | ||
| Comprehensive loss, net of tax, attributable to parent: | (2,136) | (4,475) | (1,852) | (3,345) | (1,858) | (2,906) | ||
Statements sources
The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.